Linaclotide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack organizes cited evidence, dosing-label context, safety cautions, and Australian legal status for Linaclotide.

What the sources say

Clinical trials support symptom relief for constipation-related conditions; they do not establish systemic, body-composition or general wellness effects. (Human clinical trials; Chey et al., Linaclotide for irritable bowel syndrome with constipation: randomized placebo-controlled trial (journal issue 2012-11; accessed 2026-10-28), 2026-10-28)
A Reddit poster reported perceived benefit from morning use, with a bowel movement a few hours later; other commenters described inadequate effect or intolerance. These are uncontrolled self-reports, and the original post date is not exposed beyond a relative-age label. (Community reports; Reddit r/ConstipationAdvice, "My experience with Linzess" (original post displayed as "3y ago"; accessed 2026-10-28), 2026-10-28)
Linaclotide is an oral peptide medicine registered in Australia as Constella for adults with IBS-C and chronic idiopathic constipation under the TGA-listed conditions. (Manufacturer information; Therapeutic Goods Administration, CONSTELLA (Allergan Australia Pty Ltd) registration record, 2019-06-18)
The Reddit thread includes conflicting experiences and a commenter correcting a reported milligram-versus-microgram unit error; community posts are not reliable sources for dose selection. (Community reports; Reddit r/ConstipationAdvice, "My experience with Linzess" (original post displayed as "3y ago"; accessed 2026-10-28), 2026-10-28)
Diarrhea is the most common adverse reaction in the FDA label; severe diarrhea has been associated with dehydration, dizziness, fainting, low blood pressure and electrolyte abnormalities. (Manufacturer information; U.S. FDA, LINZESS (linaclotide) prescribing information (revised 2025-11; accessed 2026-10-28), 2026-10-28)
The FDA label contraindicates use in known or suspected mechanical gastrointestinal obstruction and warns of serious dehydration risk in children younger than 2 years; these are U.S. label statements and do not replace Australian product information. (Manufacturer information; U.S. FDA, LINZESS (linaclotide) prescribing information (revised 2025-11; accessed 2026-10-28), 2026-10-28)
As of 2026-10-28, the TGA registration record identifies Constella as linaclotide hard capsules, registered on 2019-06-18 for adults with IBS-C and chronic idiopathic constipation when the stated initial measures have not been sufficient. (Educator material (not peer reviewed); Therapeutic Goods Administration, CONSTELLA (Allergan Australia Pty Ltd) registration record, 2019-06-18)
The Australian registration record is for an oral capsule product; U.S. pediatric indications or U.S. administration alternatives should not be assumed to be Australian-approved uses. (Educator material (not peer reviewed); Therapeutic Goods Administration, CONSTELLA (Allergan Australia Pty Ltd) registration record, 2019-06-18)

Sources

Dosing, stacking and protocol details are not published here.